SLC5A2 and type 1 diabetes mellitus: Finally, we discuss the use and implementation of SGLT-2 inhibition in populations of specific interest: people with type 1 diabetes, kidney transplant recipients, and people presenting with acute decompensated heart failure (Table 3).